BIO Priorities: Negotiating Medicare Reimbursement, Reducing Drug Development Times
This article was originally published in The Pink Sheet Daily
Executive Summary
"Eternal vigilance" is necessary to ensure reimbursement is not adversely affected by implementation of Medicare drug benefit law, BIO Chairman Pops says. Group will work to ensure that FDA initiatives reducing drug development times continue after McClellan departs.